Study of a new technique to analyse chemicals released by our own cells to identify latent tuberculosis

Not Applicable

• Conditions: Health Condition 1: null- Active pulmonary tuberculosis; successfully treated tuberculosis patients; people who are exposed to tuberculsis; people who are not exposed to tuberculosis

• Registration Number: CTRI/2018/01/011369
• Lead Sponsor: Manipal McGill Center for Infectious Diseases

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Patients with active pulmonary TB, latent TB, successfully treated TB and healthy controls as per the standard definitions

Exclusion Criteria

a.Pregnant women, patients with HIV/AIDS, autoimmune disorders, malignancy, patients on chemotherapy or radiotherapy

b.Extra-pulmonary TB

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ICCFC may be used as a discriminating test between active and latent TB. This will have important implications in identifying individuals with latent TB for preventive chemotherapy. Additionally, a biomarker based test for active TB is much needed to close the diagnostic gap and delay in TB diagnosis.Timepoint: 9 months

Secondary Outcome Measures

Name	Time	Method
Cytokine expression pattern in MTB antigen stimulated T cells will help in understanding the disease pathogenesis. <br/ ><br>An optimal gating strategy for ICCFC will be drafted. <br/ ><br>Timepoint: 9 months